Castro VM, Rojas CK

Language: Spanish
References: 15
Page: 183-187
PDF size: 289.64 Kb.

ABSTRACT

In past years hyperuricemia and gouty arthritis has increased their prevalence and complexity. This article objective is to review the characteristics of the disease and treatment. Different research have analyzed and compared the available therapy in search for cost-effective therapies, with well-established treatments and therapeutic targets; and reviewing emerging treatments. The ideal management in patients with hyperuricemia and gouty arthritis require a frame shift in clinical practice patterns, therapeutic target in lowering serum urate, comorbidities management and the early recognition of refractory disease.

REFERENCES

1. Bieber JD, Terkeltaub RA: Gout: on the brink of novel therapeutic options for an ancient disease. Arthritis Rheum 2004, 50:2400-2414.

2. Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA: Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004, 31:2429-2432.

3. Chao J, Terkeltaub R: A critical 3. reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr Rheumatol Rep 2009, 11:135-140.

4. Cronstein BN, Terkeltaub R: The inflammatory process of gout and its treatment. Arthritis Res Ther 2006, 8(Suppl 1):S3.

5. Endou H, Anzai N: Urate transport across the apical membrane of renal proximal tubules. Nucleosides Nucleotides Nucleic Acids 2008, 27:578-584.

6. Janssens HJ, Janssen M, Lisdonk EH, van Riel PL, van Weel C: Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet 2008, 371:1854-1860.

7. Krishnan E, Lienesch D, Kwoh CK: Gout in ambulatory care settings in the United States. J Rheumatol 2008, 35:498-501.

8. Perez-Ruiz F, Lioté F: Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum 2007, 57:1324-1328.

9. Rubin BR, Burton R, Navarra S, Antigua J, Londoño J, Pryhuber KG, Lund M, Chen E, Najarian DK, Petruschke RA, Ozturk ZE, Geba GP: Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum 2004, 50:598-606.

10. Saag KG, Choi H: Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther 2006, 8(Suppl 1):S2.

11. Terkeltaub R, Furst D, Bennett K, Kook K, Davis M: Low dose (1.8 mg) vs high dose (4.8 mg) oral colchicine regimens in patients with acute gout flare in a large, multicenter, randomized, double-blind, placebo-controlled, parallel group study [abstract]. Arthritis Rheum 2008, 58(Suppl 9):1944.

12. Terkeltaub RA: Clinical practice. Gout. N Engl J Med 2003, 349:1647-1655.

13. Terkeltaub R, Bushinsky DA, Becker MA: Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthritis Res Ther 2006, 8(Suppl 1):S4.

14. Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R: Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 2004, 31:1582-1587.

15. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, Gerster J, Jacobs J, Leeb B, Lioté F, McCarthy G, Netter P, Nuki G, Perez-Ruiz F, Pignone A, Pimentao J, Punzi L, Roddy E, Uhlig T, Zimmermann-Gorska I: EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006, 65:1312-1324.